Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

Researchers have found that semaglutide may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

Add Alzheimer's disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new ...

According to a recent study, certain classes of weight loss drugs — including Ozempic — may have positive effects on the ...

Over the last year, weight loss medications such as GLP-1s (such as compounded semaglutide, Ozempic or Wegovy) have become ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

A common diabetes and weight-loss drug may also reduce the risk of Alzheimer’s disease, according to a new study. American ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...